Citadel Advisors’s Microbot Medical MBOT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$91.3K Sell
37,900
-89,900
-70% -$201K ﹤0.01% 12096
2025
Q4
$256K Buy
127,800
+112,200
+719% +$266K ﹤0.01% 10501
2025
Q3
$47.6K Sell
15,600
-1,800
-10% -$5.61K ﹤0.01% 12235
2025
Q2
$43.8K Buy
17,400
+10,800
+164% +$25.8K ﹤0.01% 11835
2025
Q1
$9.97K Buy
+6,600
New +$11.7K ﹤0.01% 13566
2024
Q1
Sell
-1,600
Closed -$2.62K 15126
2023
Q4
$2.62K Buy
+1,600
New +$2.13K ﹤0.01% 13676

Other funds holding MBOT

Citadel Advisors's MBOT Position: Q1 2024 in Review

Citadel Advisors sold out of Microbot Medical (MBOT) in Q1 2024, closing a stake of 18,039 shares — an estimated $29.6K sold.

Citadel Advisors first reported a position in MBOT in Q2 2013 and held it in 19 quarters. The position peaked at $140K in Q1 2021. 33 funds tracked by Wall St. Rank hold MBOT as of Q1 2024.

  • Citadel Advisors reported no remaining Microbot Medical position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 18,039 Microbot Medical shares in Q1 2024, an estimated $29.6K.
  • Citadel Advisors first reported a position in Microbot Medical in Q2 2013 and held it in 19 quarters.
  • Citadel Advisors's Microbot Medical position peaked at $140K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Microbot Medical as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.